Abstract
Oncostatin M (OSM), a cytokine of the interleukin-6 family, induces growth arrest and differentiation of osteoblastic cells into glial-like/osteocytic cells. Here, we asked whether OSM regulates apoptosis of normal or transformed (osteosarcoma) osteoblasts. We show that OSM sensitizes cells to apoptosis induced by various death inducers such as staurosporine, ultraviolet or tumor necrosis factor-α. Apoptosis is mediated by the mitochondrial pathway, with release of cytochrome c from the mitochondria to the cytosol and activation of caspases-9 and -3. DNA micro-arrays revealed that OSM modulates the expression of Bax, Bad, Bnip3, Bcl-2 and Mcl-1. Pharmacological inhibitors, dominant-negative signal transducer and activator of transcriptions (STATs), stable RNA interference and knockout cells indicated that the transcription factors p53 and STAT5, which are activated by OSM, are implicated in the sensitization to apoptosis, being responsible for Bax induction and Bcl-2 reduction, respectively. These results indicate that, in addition to growth arrest and induced differentiation, OSM also sensitizes normal and transformed osteoblasts to apoptosis by a mechanism implicating (i) activation and nuclear translocation of STAT5 and p53 and (ii) an increased Bax/Bcl-2 ratio. Therefore, association of OSM with kinase inhibitors such as Sts represents new therapeutic opportunities for wild-type p53 osteosarcoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Auernhammer CJ, Dorn F, Vlotides G, Hengge S, Kopp FB, Spoettl G et al. (2004). The oncostatin M receptor/gp130 ligand murine oncostatin M induces apoptosis in adrenocortical Y-1 tumor cells. J Endocrinol 180: 479–486.
Auguste P, Guillet C, Fourcin M, Olivier C, Veziers J, Pouplard-Barthelaix A et al. (1997). Signaling of type II oncostatin M receptor. J Biol Chem 272: 15760–15764.
Battle TE, Frank DA . (2002). The role of STATs in apoptosis. Curr Mol Med 2: 381–392.
Baumann H, Wang Y, Richards CD, Jones CA, Black TA, Gross KW . (2000). Endotoxin-induced renal inflammatory response. Oncostatin M as a major mediator of suppressed renin expression. J Biol Chem 275: 22014–22019.
Bellido T, Borba VZ, Roberson P, Manolagas SC . (1997). Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. Endocrinology 138: 3666–3676.
Bellido T, O’Brien CA, Roberson PK, Manolagas SC . (1998). Transcriptional activation of the p21(WAF1, CIP1, SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. J Biol Chem 273: 21137–21144.
Buitenhuis M, Coffer PJ, Koenderman L . (2004). Signal transducer and activator of transcription 5 (STAT5). Int J Biochem Cell Biol 36: 2120–2124.
Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP et al. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497–1501.
Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ . (1991). Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6: 1791–1797.
Chandar N, Billig B, McMaster J, Novak J . (1992). Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 65: 208–214.
Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K et al. (1999). Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13: 2604–2616.
Chen SH, Benveniste EN . (2004). Oncostatin M: a pleiotropic cytokine in the central nervous system. Cytokine Growth Factor Rev 15: 379–391.
Chipoy C, Berreur M, Couillaud S, Pradal G, Vallette F, Colombeix C et al. (2004). Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3. J Bone Miner Res 19: 1850–1861.
Debierre-Grockiego F . (2004). Anti-apoptotic role of STAT5 in haematopoietic cells and in the pathogenesis of malignancies. Apoptosis 9: 717–728.
Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M et al. (1990). p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 10: 5772–5781.
Eskes R, Desagher S, Antonsson B, Martinou JC . (2000). Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 20: 929–935.
Florenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O . (1994). MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst 86: 1297–1302.
Fuchs B, Pritchard DJ . (2002). Etiology of osteosarcoma. Clin Orthop Relat Res 397: 40–52.
Grant SL, Begley CG . (1999). The oncostatin M signalling pathway: reversing the neoplastic phenotype? Mol Med Today 5: 406–412.
Haupt S, Berger M, Goldberg Z, Haupt Y . (2003). Apoptosis − the p53 network. J Cell Sci 116: 4077–4085.
Heath C, Cross NC . (2004). Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1. J Biol Chem 279: 6666–6673.
Jilka RL, Weinstein RS, Bellido T, Parfitt AM, Manolagas SC . (1998). Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J Bone Miner Res 13: 793–802.
Kamiya A, Kinoshita T, Ito Y, Matsui T, Morikawa Y, Senba E et al. (1999). Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer. EMBO J 18: 2127–2136.
Kashkar H, Wiegmann K, Yazdanpanah B, Haubert D, Kronke M . (2005). Acid sphingomyelinase is indispensable for UV light-induced Bax conformational change at the mitochondrial membrane. J Biol Chem 280: 20804–20813.
Le Meur N, Lamirault G, Bihouee A, Steenman M, Bedrine-Ferran H, Teusan R et al. (2004). A dynamic, web-accessible resource to process raw microarray scan data into consolidated gene expression values: importance of replication. Nucleic Acids Res 32: 5349–5358.
Lengner CJ, Steinman HA, Gagnon J, Smith TW, Henderson JE, Kream BE et al. (2006). Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling. J Cell Biol 172: 909–921.
Nosaka T, Kawashima T, Misawa K, Ikuta K, Mui AL, Kitamura T . (1999). STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells. EMBO J 18: 4754–4765.
Oren M . (2003). Decision making by p53: life, death and cancer. Cell Death Differ 10: 431–442.
Qin XF, An DS, Chen IS, Baltimore D . (2003). Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 100: 183–188.
Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N, Moriggl R et al. (2000). Bone homeostasis in growth hormone receptor-null mice is restored by IGF-I but independent of Stat5. J Clin Invest 106: 1095–1103.
Stephanou A, Brar BK, Knight RA, Latchman DS . (2000). Opposing actions of STAT-1 and STAT-3 on the Bcl-2 and Bcl-x promoters. Cell Death Differ 7: 329–330.
Stott FJ, Bates S, James MC, McConnell BB, Starborg M, Brookes S et al. (1998). The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J 17: 5001–5014.
Thornborrow EC, Manfredi JJ . (1999). One mechanism for cell type-specific regulation of the bax promoter by the tumor suppressor p53 is dictated by the p53 response element. J Biol Chem 274: 33747–33756.
Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A . (2004). STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem 279: 5811–5820.
Trichet V, Benezech C, Dousset C, Gesnel MC, Bonneville M, Breathnach R . (2006). Complex interplay of activating and inhibitory signals received by Vgamma9Vdelta2 T cells revealed by target cell beta2-microglobulin knockdown. J Immunol 177: 6129–6136.
Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y et al. (1994). Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res 54: 3042–3048.
Wang X, Kua HY, Hu Y, Guo K, Zeng Q, Wu Q et al. (2006). p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J Cell Biol 172: 115–125.
Wei Q . (2005). Pitx2a binds to human papillomavirus type 18 E6 protein and inhibits E6-mediated P53 degradation in HeLa cells. J Biol Chem 280: 37790–37797.
Acknowledgements
We thank Isabelle Guisle-Marsollier (Inserm U533, Nantes, France) for her help on micro-arrays, and Caroline Colombeix (IFR26, Nantes, France) for the Confocal Microscopy. This work was supported by Inserm, the Ministère de la Recherche and La Ligue Contre le Cancer. CC is a recipient from of fellowship from the Région Pays de la loire.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc).
Rights and permissions
About this article
Cite this article
Chipoy, C., Brounais, B., Trichet, V. et al. Sensitization of osteosarcoma cells to apoptosis by oncostatin M depends on STAT5 and p53. Oncogene 26, 6653–6664 (2007). https://doi.org/10.1038/sj.onc.1210492
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210492
Keywords
This article is cited by
-
STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells
Oncogene (2019)
-
Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation
Oncogene (2015)
-
Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta
European Journal of Human Genetics (2014)